Exelixis (EXEL) Long-Term Deferred Tax (2018 - 2026)
Exelixis (EXEL) posted quarterly Long-Term Deferred Tax of $293.7 million for Q2 2026, down 29.9% year-over-year from $419.0 million in Q2 2025, and little changed quarter-over-quarter from $292.6 million in Q1 2026.
Analysis
Exelixis (EXEL) Long-Term Deferred Tax (2018 - 2026) Analysis & Trends
Exelixis' Long-Term Deferred Tax history runs 9 years deep, the most recent figure standing at $293.7 million for Q2 2026.
- In Q2 2026, Long-Term Deferred Tax fell 29.9% year-over-year to $293.7 million; the TTM figure through Apr 2026 stood at $293.7 million (down 29.9% YoY), while the FY2026 annual figure was $292.6 million, down 30.34% from the prior year.
- Long-Term Deferred Tax for Q2 2026 stood at $293.7 million, roughly flat from $292.6 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $420.0 million in Q1 2025, with the low at $98.0 million in Q2 2022.
- The 5-year median for Long-Term Deferred Tax is $293.7 million (2026), against an average of $291.6 million.
- The sharpest annual moves came in 2022 and 2023: Long-Term Deferred Tax plunged 38.98% in 2022, then jumped 134.29% in 2023.
- Exelixis' Long-Term Deferred Tax stood at $231.1 million in 2022, then surged by 56.27% to $361.1 million in 2023, then dropped by 0.63% to $358.9 million in 2024, then rose by 16.64% to $418.6 million in 2025, then slipped by 29.83% to $293.7 million in 2026.
- Business Quant data shows EXEL's Long-Term Deferred Tax at $293.7 million in Q2 2026, $292.6 million in Q1 2026, and $418.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 294.21 Mn |
| Apr 3, 2026 | 293.73 Mn |
| Jan 2, 2026 | 292.58 Mn |
| Oct 3, 2025 | 418.58 Mn |
| Jul 4, 2025 | 419.24 Mn |
| Apr 4, 2025 | 419.05 Mn |
| Jan 3, 2025 | 420.03 Mn |
| Sep 27, 2024 | 358.87 Mn |
| Jun 28, 2024 | 361.56 Mn |
| Mar 29, 2024 | 361.58 Mn |
| Dec 29, 2023 | 361.15 Mn |
| Sep 29, 2023 | 230.99 Mn |
| Jun 30, 2023 | 231.12 Mn |
| Mar 31, 2023 | 229.60 Mn |
| Dec 30, 2022 | 231.11 Mn |
| Sep 30, 2022 | 116.42 Mn |
| Jul 1, 2022 | 113.96 Mn |
| Apr 1, 2022 | 98.00 Mn |
| Dec 31, 2021 | 111.66 Mn |
| Oct 1, 2021 | 125.30 Mn |